1. Low-Dose Colchicine for the Management of Coronary Artery Disease.
- Author
-
Tardif JC and Marquis-Gravel G
- Subjects
- Colchicine, Humans, Atherosclerosis, Coronary Artery Disease drug therapy, Myocardial Infarction
- Abstract
Competing Interests: Funding Support and Author Disclosures Dr Tardif has received grant support from Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Novartis, Pfizer, RegenXBio, and Sanofi; has received honoraria from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals, Pendopharm, and Sanofi; has minor equity interest in DalCor Pharmaceuticals; and is mentioned as an author on submitted patents on pharmacogenomics-guided CETP inhibition, use of colchicine after myocardial infarction, and use of colchicine in COVID-19 (he has waived his rights in the colchicine patents and does not stand to gain financially). Dr Marquis-Gravel has received research grants from Bayer; has received speaker honoraria from Novartis; and has served on national advisory boards for Servier, JAMP, and Bayer.
- Published
- 2021
- Full Text
- View/download PDF